Replies to post #480824 on NorthWest Biotherapeutics Inc (NWBO)

[Margin Buu]

Nothing factual, yawn.

[DavidW2]

After so many years waiting....I agree

1. There will be no TLD PR this year
2. There will be no Journal this year

I think NWBO management will just file BLA to MHRA. If accept, then approval from MHRA will come in second of year 2023.

After receive approval from MHRA next year, then Journal will come, BLA for FDA will be filed by the end of year 2023.

[ccie1024]

TOTAL DYSFUNCTION[color=red][/color].

ZERO[color=red][/color]

You just bricked my iPhone…

[Horseb4CarT]

So much bullsh_t !!!

We have:

1. TLD the 2 main endpoints met with statistical significance

2. Certified Sawston production

3. Making and administering dcvaxL in the UK under specials

4. Patents, patents, and more patents

5. Worlds foremost neurosurgeons onboard

6. ASCO this weekend will be positive

7. Peer reviewed trial results published in journal any day now

I could go on, however the most important indisputable facts are the

Long term survivors scoreboard:

DCVax L - increasing number > ten or fifteen alive 8-20 years
Any and all other treatment - ZERO !

DCVAXL - mOS improvement for rGBM
Any and all other treatment - No mOS Improvement !

DcvaxL improved mOS for nGBM !

DcvaxL improved mOS for rGBM (the oncologists gasped at NYAS !

[Extremist223]

Same style of argument for the last 6 years. Just different names come and go. Boiler room is in full digital effect.

[X Master]

Primary Endpoint met (mOS in nGBM), with statistical significance.
Secondary Endpoint met (mOS in rGBM), with statistical significance.
Excellent safety profile:
2193 doses of DCVax-L administered
Only 5 SAEs at least possibly related
No autoimmune reactions
No cytokine storms

ZERO? Safety reactions?

[MasterBlastr]

Damn it - you woke up Curly -